PATENT CLAIM ANALYSIS

Application Number: 15904265
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "220000"]

Abstract:
Provided herein are isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers, antibody-drug conjugates comprising them and methods of use for killing cells and treating disease.

Claim (Index 12):
An antibody-drug conjugate having a structure of Formula II:\n wherein:  is an antibody or antibody fragment; W\u2014R M  is a linking moiety formed by W and R x , wherein W is a moiety attached a natural or unnatural amino acid residue of the antibody/antibody fragment and R x  is a succinimidyl, maleimidyl, cylooctynyl, aminooxy, bisulfonyl, sulfonyl, or isothiocyanate moiety, such that W\u2014R M  is a disulfide, a thiolated succinimidyl, an amino substituted succinimidyl, a (cyclooctyl)-1, 4 triazolyl, oxime substituted N-glycan, oxime, a substituted bis-sulfopropyl, a sulfonamidyl, an amide, or a thiocarbamate moiety; L is a Linker L, wherein the Linker L is a bond or is a moiety having 1-200 nonhydrogen atoms selected from C, N, O, S, or halogen, and optionally incorporates ether, oxo, carboxamidyl, urethanyl, amino acid, heterocyclic, aromatic or heteroaromatic moieties; IQB-CBI is a compound having a structure of Formula I: wherein:\n the dotted bond shown between \u2014C(R a )\u2014 and \u2014N(R b )\u2014 is independently a single bond or a double bond;\n when a double bond is present between \u2014C(R a )\u2014 and \u2014N(R b )\u2014, the \u2014C(R a )\u2014 is olefinic and has a substituent R a , and R b  of the \u2014N(R b )\u2014 is not present; \n when a single bond is present between \u2014C(R a )\u2014 and \u2014N(R b )\u2014, the \u2014C(R a )\u2014 is saturated and has a hydrogen substituent in addition to the R a  substituent and R b  of the \u2014N(R b )\u2014 is present; \n \n R a  is independently H, or OH; \n if present, R b  is H or is a bond to the Linker L; \n R 2  is selected from H, OH, C 1 -C 10  alkyl, C 2 -C 10  alkenyl or C 2 -C 10  alkynyl; \n R 3 , R 3\u2032 , R 4 , R 4\u2032 , R 6\u2032  and R 6  are each independently selected from H, OH, C 1 -C 10  alkyl, C 2 -C 10  alkenyl or C 2 -C 10  alkynyl, or, if Y is N, is not present; \n each of R 5  or R 5\u2032  is independently NH 2 , CO 2 H, H, OH, C 1 -C 10  alkyl, C 2 -C 10  alkenyl, C 2 -C 10  alkynyl, is a bond to the Linker L, or, if Y is N, is not present; \n R 7  is H; \n G\u2032-Rb\u2032 is selected from OH, O-L, NH 2 , or NH-L, wherein L is the Linker L; \n each Y is, independently, N or C; \n each D is, independently, (CH 2 ) n  where n=0-4, provided that at least one D is (CH 2 ) n  where n=1-4; \n X1 is a spacer selected from the group consisting of the following: \n                                     wherein at least one of R b , R 5 , R 5\u2032  and G-R b\u2032  is a bond linked to Linker L or comprises Linker L; and wherein the IQB-CBI compound has S,S stereochemistry.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 88.0
- Lexical Diversity: 1.16129
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15335164', '15048865', '14305643', '15182444', '15182429']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8472946006328105
- 35 USC 102 Novelty (BERT): 0.5711281391822746
- Combined Prediction Score: 0.8196779544877568
- Mean Citation Score: 413.66847400000006
- Max Citation Score: 470.99097
- Similarity Product: 399.6408413718116

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test